Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Gettinger SN, et al. Among authors: hirsch fr. JAMA Oncol. 2021 Sep 1;7(9):1368-1377. doi: 10.1001/jamaoncol.2021.2209. JAMA Oncol. 2021. PMID: 34264316 Free PMC article. Clinical Trial.
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR; Southwest Oncology Group. Hirsch FR, et al. J Clin Oncol. 2005 Oct 1;23(28):6838-45. doi: 10.1200/JCO.2005.01.2823. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998906 Clinical Trial.
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Cappuzzo F, et al. Among authors: hirsch fr. Ann Oncol. 2006 Jul;17(7):1120-7. doi: 10.1093/annonc/mdl077. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600976 Free article.
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr. Hirsch FR, et al. Ann Oncol. 2007 Apr;18(4):752-60. doi: 10.1093/annonc/mdm003. Epub 2007 Feb 22. Ann Oncol. 2007. PMID: 17317677 Free article.
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Hesketh PJ, et al. Among authors: hirsch fr. J Thorac Oncol. 2008 Sep;3(9):1026-31. doi: 10.1097/JTO.0b013e318183aa1f. J Thorac Oncol. 2008. PMID: 18758306 Free PMC article. Clinical Trial.
472 results